GSK v. Teva 'Skinny Label' Ruling Positive for Amarin (AMRN) - Citi

Citi analyst Joel Beatty reiterated a Buy rating and $12.00 price target on Amarin Corporation (NASDAQ: AMRN), saying Friday's GSK versus Teva 'skinny label' appeals court decision appears to have a "meaningfully favorable readthrough" for Amarin.

Beatty commented, "On Friday, a U.S. appeals court ruled that Teva infringed on GSK’s carvedilol heart failure patent, despite Teva’s generic carvedilol launching with a ‘skinny label’ that ‘carved out’ the heart failure indication. We believe this ruling could potentially benefit AMRN by making potential generic Vascepa competitors 1) more hesitant to launch a generic competitor, 2) more open to a settlement with AMRN, and 3) more likely to be assessed large and meaningful damages if a generic Vascepa is launched."

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

Shares of Amarin Corporation closed at $4.50 yesterday.

You May Also Be Interested In

• Tesla readies August launch of CyberCab - The Information
• Deutsche Bank Downgrades Netskope (NTSK) to Hold on Valuation
• Wolfpack Research: 'we are short FTK because their $400m deal has been canceled'